联合治疗与单一药物治疗糖尿病肾病蛋白尿的疗效分析  

Combined Treatment and Single Drug Treatment of Diabetic Nephrotic Proteinuria

作　　者：马艳 

机构地区：[1]江苏省邳州市人民医院肾内科,江苏邳州221300

出　　处：《中国继续医学教育》2017年第33期88-89,共2页China Continuing Medical Education

摘　　要：目的探讨前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床有效性与安全性。方法以2015年6月—2017年6月我院60例糖尿病肾病蛋白尿患者为研究对象,依据治疗方法不同分为实验组(前列地尔联合贝那普利,30例)和对照组(前列地尔,30例),对比观察两组临床疗效,统计不良反应。结果实验组治疗总有效率(93.33%)与对照组(70.00%)比较,差异有统计学意义(P<0.05)。实验组不良反应率(6.67%)与对照组(3.33%)比较,差异无统计学意义(P>0.05)。结论前列地尔联合贝那普利治疗糖尿病肾病蛋白尿效果显著,安全可靠。Objective To investigate the clinical efficacy and safety of alprostadil combined with benazepril in the treatment of diabetic nephropathy with proteinuria. Methods 60 cases of diabetic nephrotic proteinuria from June 2015 to June 2017 in our hospital were studied. According to different treatment methods they divided into experimental group （alprostadil combined benazepril, 30 cases） and control group （alprostadil, 30 cases）. The clinical effects of the two groups were compared and observed, and the adverse reactions were statistically analyzed. Results The total effective rate of treatment in the experimental group （93.33%） was compared with the control group （70.00%）, the difference was statistically significant （P 〈 0.05）. The adverse reaction rate of the experimental group （6.67%） was compared with the control group （3.33%）, the difference was not statistically signifcant （P 〉 0.05）. Conclusion Alprostadil combined with benazepril in the treatment of diabetic nephrotic proteinuria is signifcant, safe and reliable.

关 键 词：糖尿病肾病 蛋白尿 前列地尔 贝那普利 

分 类 号：R587[医药卫生—内分泌]